From the Departments of Radiology (B.T., M.D.N.) and Pediatrics (M.B.N., G.D.), Children's Hospital Los Angeles, 4650 Sunset Blvd, MS 81, Los Angeles, CA 90027; and Departments of Radiology (C.S.J.L.), Neurology and Radiology (S.Y.C.), and Pediatrics (M.B.N.), Keck School of Medicine of the University of Southern California, Los Angeles, Calif.
Radiology. 2018 Oct;289(1):188-194. doi: 10.1148/radiol.2018173057. Epub 2018 Jul 10.
Purpose To determine whether treatment affects MRI signal intensity in pediatric patients with primary brain tumors independent of the administration of macrocyclic gadolinium-based contrast agents (GBCAs). Materials and Methods This retrospective, single-center study included 78 patients (mean age, 7.7 years ± 5.4) with primary brain tumors who underwent macrocyclic GBCA-enhanced MRI from 2015 to 2018. Three groups were compared: (a) patients who had undergone radiation therapy (37 patients, 26 of whom had undergone concurrent chemotherapy), (b) patients who had undergone chemotherapy only (17 patients), and (c) patients who had received no treatment ("no-treatment group," 24 patients). The signal intensity in the globus pallidus (GP), thalamus, dentate nucleus (DN), and pons was measured on unenhanced T1-weighted images. GP-to-thalamus and DN-to-pons signal intensity ratios were compared among groups with analysis of variance by using the Kruskal-Wallis test, followed by post hoc pairwise tests with Tukey adjustment, and were analyzed relative to group, total cumulative doses of GBCA, age, and sex with multivariable linear models. Results The mean number of GBCA-enhanced MRI examinations in the radiation therapy, chemotherapy-only, and no-treatment groups was 7.11, 7.29, and 4.96, respectively (P < .01 for the radiation therapy and chemotherapy groups compared with the no-treatment group). The DN-to-pons ratio in the radiation therapy group was higher than that in both the no-treatment group and the chemotherapy-only group (P < .01 for both). There was no significant difference in the DN-to-pons ratios between the chemotherapy-only group and the no-treatment group (P = .99). The GP-to-thalamus ratios did not differ among all three groups (P = .09). There was no dose-dependent effect of GBCA on the DN-to-pons and GP-to-thalamus ratios when adjusting for the effects of treatment (P = .21 and P = .38, respectively). Conclusion Brain irradiation contributes to a higher dentate nucleus signal intensity in pediatric patients with brain tumor independent of the administration of macrocyclic gadolinium-based contrast agents. © RSNA, 2018.
目的 本研究旨在确定在未使用大环类钆对比剂(GBCA)的情况下,治疗是否会影响小儿脑肿瘤患者的 MRI 信号强度。
材料与方法 本回顾性单中心研究纳入了 2015 年至 2018 年期间行大环类 GBCA 增强 MRI 检查的 78 例(平均年龄 7.7 岁±5.4 岁)原发性脑肿瘤患儿。比较了 3 组患儿:(a)放疗组(37 例,其中 26 例接受同期化疗);(b)化疗组(17 例);(c)未治疗组(“未治疗组”,24 例)。在未增强 T1 加权图像上测量苍白球(GP)、丘脑、齿状核(DN)和脑桥的信号强度。采用方差分析比较各组间的 GP-丘脑和 DN-脑桥信号强度比,采用 Kruskal-Wallis 检验,然后采用 Tukey 调整后的事后两两比较,并采用多变量线性模型分析与组、GBCA 总累积剂量、年龄和性别相关的结果。
结果 放疗组、化疗组和未治疗组的平均 GBCA 增强 MRI 检查次数分别为 7.11、7.29 和 4.96(放疗组和化疗组与未治疗组相比,P<.01)。放疗组的 DN-脑桥比高于未治疗组和化疗组(均 P<.01)。化疗组与未治疗组的 DN-脑桥比无显著差异(P=.99)。3 组间的 GP-丘脑比无差异(P=.09)。校正治疗效果后,GBCA 对 DN-脑桥和 GP-丘脑比无剂量依赖性影响(分别为 P=.21 和 P=.38)。
结论 脑照射可导致脑肿瘤患儿脑内齿状核信号强度增高,与大环类钆对比剂的使用无关。
©RSNA,2018。